Genomics Collaborative, Inc.

Description

GCI has developed expertise in applying the science of human genetics to drug and diagnostic discovery decisions. The Company's approach links human genes, proteins, and clinical outcomes through proprietary technology platforms. GCI's state-of-the-art technology offers a highly efficient method to validate genomics-based drug and diagnostic targets, and has already been validated through partnerships with more than 30 pharmaceutical and biotechnology companies. GCI believes that to broadly apply targets to drug or diagnostic development in the pharmaceutical market, they must be validated in human populations.The Company provides a powerful combination of resources through its target validation program, GCI Access™. First, the program offers customized access to GCI's Global Repository™ of appropriately consented clinical research material. This includes human DNA, RNA, sera, and snap-frozen tissue samples linked to detailed medical information collected from patient populations worldwide. To date, the Company has recruited over 120,000 patients in building Global Repository™, and prospective collections continue in various disease states. Additionally, the GCI Access™ program offers customers expertise in proficiently designing and conducting human genetic studies geared towards the development of therapeutics and diagnostics.Together with its study design, statistics, and analysis capabilities, GCI offers a suite of high throughput genomic analysis tools, including: SNP genotyping, DNA sequencing, RT-PCR, and gene expression analyses. These tools can be applied to leverage the assets of the Company's Global Repository™ in research settings. This combination places GCI at the forefront of the next generation of target validation and drug discovery.

Companies nearby